2-(M-Phenyl-piperazinomethyl)-3H-chinazolon-4 | 19062-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(M-Phenyl-piperazinomethyl)-3H-chinazolon-4
• 英文别名: 2-[(4-phenylpiperazin-1-yl)methyl]quinazolin-4(3H)-one；2-(4-phenyl-piperazin-1-ylmethyl)-3H-quinazolin-4-one；4(3H)-Quinazolinone, 2-((4-phenyl-1-piperazinyl)methyl)-；2-[(4-phenylpiperazin-1-yl)methyl]-3H-quinazolin-4-one
• CAS: 19062-53-4
• 化学式: C₁₉H₂₀N₄O
• mdl: MFCD06755255
• 分子量: 320.394
• InChiKey: BDTMVYOHGOZGCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基苯甲酰胺 在 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 6.0h， 生成 2-(M-Phenyl-piperazinomethyl)-3H-chinazolon-4
  参考文献：
  名称：

  Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as α1-adrenoreceptor antagonists

  摘要：

  Three series of new 2-[(4-substituted piperazin-1-yl) methyliquinazolin-4(3H)-ones 4a-c, Ethyl 6,7-dimethoxy-4-oxo-3-[2-(4-substituted piperazin-1-yl)acetamido/propanamido]-3,4-dihydroquinazoline-2-carboxylates 9a-f and their 2-methyl analogues 13a-I were designed and synthesized as promising alpha(1)-adrenoceptor antagonists. The final compounds were evaluated for their in vivo hypotensive activity in normotensive cats. The most potent hypotensive quinazolinone derivatives 4b, 9e, 13i, 13j were further tested on isolated thoracic aortic rings of male Wister rats. All the tested compounds displayed alpha(1)-blocking activity with IC50 ranging from 0.2 to 0.4 mM less than prazosin. Furthermore, in the present work, molecular modeling study using Accelrys Discovery Studio 2.1 software was performed by mapping the synthesized compounds to the alpha(1)-adrenoceptor antagonist hypothesis in order to predict their mechanism of action. Compound 13j which has the best-fitting score displayed the highest in vivo and in vitro activity among the tested compounds. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.045

文献信息

• Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders
  申请人：Tworowski Dmitry

  公开号：US20100029671A1

  公开（公告）日：2010-02-04

  Novel heterocyclic compounds, which exhibit a dopamine receptor (preferably a D4 receptor) agonistic activity, and/or a PDE5 inhibitory activity, processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of sexual disorders such as decreased libido, orgasm disorder and erectile dysfunction are disclosed.

  本发明揭示了一种新型杂环化合物，其表现出多巴胺受体（优选为D4受体）激动活性和/或PDE5抑制活性，以及制备该化合物的方法，含有该化合物的药物组合物以及将其用于治疗性功能障碍，如性欲减退、性高潮障碍和勃起功能障碍的用途。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS
  申请人：ATIR Holding S.A.

  公开号：US20130072479A1

  公开（公告）日：2013-03-21

  Novel heterocyclic compounds, which exhibit a dopamine receptor (preferably a D4 receptor) agonistic activity, and/or a PDE5 inhibitory activity, processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of sexual disorders such as decreased libido, orgasm disorder and erectile dysfunction are disclosed.

  本发明涉及一种新型杂环化合物，该化合物表现出多巴胺受体（优选为D4受体）的激动作用和/或PDE5抑制活性，以及制备该化合物的方法，含有该化合物的制药组合物以及在治疗性欲减退、性高潮障碍和勃起功能障碍等性障碍方面的应用。
• US8349850B2
  申请人：——

  公开号：US8349850B2

  公开（公告）日：2013-01-08
• US8614319B2
  申请人：——

  公开号：US8614319B2

  公开（公告）日：2013-12-24
• US9034872B2
  申请人：——

  公开号：US9034872B2

  公开（公告）日：2015-05-19